Lead Product(s) : Aumolertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
Details : Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.
Brand Name : EQ143
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 29, 2022
Lead Product(s) : Aumolertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aumolertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Abdul Latif Jameel Health
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
Brand Name : EQ143
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 22, 2021
Lead Product(s) : Aumolertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Abdul Latif Jameel Health
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Aumolertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CM Life Sciences
Deal Size : $2,000.0 million
Deal Type : Merger
Details : Proceeds expand balance sheet to ~$2.0 billion and will be used for “new pharma” platforms. EQRx’s growing pipeline includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and other cli...
Brand Name : EQ143
Molecule Type : Small molecule
Upfront Cash : $2,000.0 million
August 06, 2021
Lead Product(s) : Aumolertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CM Life Sciences
Deal Size : $2,000.0 million
Deal Type : Merger
Lead Product(s) : Aumolertinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : EQRx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib
Details : Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $100.0 million
July 23, 2020
Lead Product(s) : Aumolertinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : EQRx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?